Skip to main content
Erschienen in: Cancer Causes & Control 10/2008

01.12.2008 | Original Paper

Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer

verfasst von: Bette J. Caan, Marilyn L. Kwan, Georgina Hartzell, Adrienne Castillo, Martha L. Slattery, Barbara Sternfeld, Erin Weltzien

Erschienen in: Cancer Causes & Control | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

We examined the association between body mass index (BMI) around the time of diagnosis, weight change post-diagnosis, and breast cancer prognosis in a prospective cohort study of 1,692 breast cancer survivors.

Methods

Pre-diagnosis weight, weight at study entry, and height was obtained from mailed questionnaires and then weight change and BMI were calculated. After approximately seven years of follow-up, 207 recurrences, 99 deaths due to breast cancer, and 162 deaths due to any cause were reported. Delayed entry Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI), controlling for treatment and known prognostic factors.

Results

Being obese one year before diagnosis was associated with an increased risk of death from any cause (HR = 1.6; 95% CI: 1.1–2.3) and a suggestion of increased risk of death from breast cancer (HR = 1.6; 95% CI: 0.9–2.7). However, weight gain up to four years after a breast cancer diagnosis was not associated with an increased risk of recurrence or death from any cause nor did moderate weight loss (5–10%) decrease risk of these outcomes. There was some evidence that women who had larger weight losses (≥10%) between pre-diagnosis and study entry had an increased risk of recurrence (HR = 1.7; 95% CI 1.0–2.6) and death due to any cause (HR = 2.1; 95% CI 1.3–3.4) compared to being weight stable. This elevated risk was more pronounced among women who were obese before diagnosis (BMI ≥ 30 kg/m2) or who had ER− or PR− tumors.

Conclusion

We found that being obese before breast cancer diagnosis was associated with increased risk of recurrence and poorer survival, corroborating results from previous studies. However, weight gain after diagnosis did not confer additional risk. Body weight pre-diagnosis appears to be the strongest predictor of an adverse breast cancer prognosis.
Literatur
1.
Zurück zum Zitat Demark-Wahnefried W, Peterson BL, Winer EP et al (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19(9):2381–2389PubMed Demark-Wahnefried W, Peterson BL, Winer EP et al (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19(9):2381–2389PubMed
2.
Zurück zum Zitat Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–528. Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–528.
4.
Zurück zum Zitat Lankester KJ, Phillips JE, Lawton PA (2002) Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy. Clin Oncol (R Coll Radiol) 14(1):64–67. doi:10.1053/clon.2001.0014 Lankester KJ, Phillips JE, Lawton PA (2002) Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy. Clin Oncol (R Coll Radiol) 14(1):64–67. doi:10.​1053/​clon.​2001.​0014
5.
6.
Zurück zum Zitat Saquib N, Flatt SW, Natarajan L et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat 105(2):177–186. doi:10.1007/s10549-006-9442-2 PubMedCrossRef Saquib N, Flatt SW, Natarajan L et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat 105(2):177–186. doi:10.​1007/​s10549-006-9442-2 PubMedCrossRef
7.
8.
Zurück zum Zitat Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMed Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMed
10.
Zurück zum Zitat Rock CL, Demark-Wahnefried W (2002) Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr 132(11 Suppl):3504S–3507SPubMed Rock CL, Demark-Wahnefried W (2002) Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr 132(11 Suppl):3504S–3507SPubMed
17.
Zurück zum Zitat Bonomi P, Bunting N, Fishman D (1984) Weight gain during breast cancer evaluated in relation to disease-free survival (DFS). Breast Cancer Res Treat 4:339 Bonomi P, Bunting N, Fishman D (1984) Weight gain during breast cancer evaluated in relation to disease-free survival (DFS). Breast Cancer Res Treat 4:339
18.
Zurück zum Zitat Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8(8):1327–1334PubMed Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8(8):1327–1334PubMed
19.
Zurück zum Zitat Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman JR (1986) Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat 7(1):23–30. doi:10.1007/BF01886732 PubMedCrossRef Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman JR (1986) Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat 7(1):23–30. doi:10.​1007/​BF01886732 PubMedCrossRef
21.
23.
Zurück zum Zitat Levine EG, Raczynski JM, Carpenter JT (1991) Weight gain with breast cancer adjuvant treatment. Cancer 67(7):1954–1959. doi :10.1002/1097-0142(19910401)67:7<1954::AID-CNCR2820670722>3.0.CO;2-ZPubMedCrossRef Levine EG, Raczynski JM, Carpenter JT (1991) Weight gain with breast cancer adjuvant treatment. Cancer 67(7):1954–1959. doi :10.1002/1097-0142(19910401)67:7<1954::AID-CNCR2820670722>3.0.CO;2-ZPubMedCrossRef
25.
Zurück zum Zitat Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML (2005) Life After Cancer Epidemiology (LACE) study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control 16(5):545–556. doi:10.1007/s10552-004-8340-3 PubMedCrossRef Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML (2005) Life After Cancer Epidemiology (LACE) study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control 16(5):545–556. doi:10.​1007/​s10552-004-8340-3 PubMedCrossRef
27.
Zurück zum Zitat Bantle JP, Wylie-Rosett J, Albright AL et al (2006) Nutrition recommendations and interventions for diabetes–2006: a position statement of the American Diabetes Association. Diabetes Care 29(9):2140–2157. doi:10.2337/dc06-9914 PubMedCrossRef Bantle JP, Wylie-Rosett J, Albright AL et al (2006) Nutrition recommendations and interventions for diabetes–2006: a position statement of the American Diabetes Association. Diabetes Care 29(9):2140–2157. doi:10.​2337/​dc06-9914 PubMedCrossRef
28.
Zurück zum Zitat Doyle C, Kushi LH, Byers T et al (2006) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56(6):323–353PubMedCrossRef Doyle C, Kushi LH, Byers T et al (2006) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56(6):323–353PubMedCrossRef
30.
Zurück zum Zitat Cox DR, Oakes D (1994) Analysis of survival data. Monographs in statistics and applied probability, vol 21. Chapman & Hall Cox DR, Oakes D (1994) Analysis of survival data. Monographs in statistics and applied probability, vol 21. Chapman & Hall
31.
Zurück zum Zitat Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Statistics for biology and health. Springer-Verlag, New York Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Statistics for biology and health. Springer-Verlag, New York
33.
Zurück zum Zitat Rothman K, Greenland S (1998) Modern epidemiology, 2nd edn. Lippincott-Raven Publishers, Philadelphia Rothman K, Greenland S (1998) Modern epidemiology, 2nd edn. Lippincott-Raven Publishers, Philadelphia
34.
Zurück zum Zitat Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1(1):43–46PubMedCrossRef Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1(1):43–46PubMedCrossRef
35.
Zurück zum Zitat Savitz D (2003) Interpreting epidemiologic evidence: strategies for study design and analysis. Oxford University Press, New York Savitz D (2003) Interpreting epidemiologic evidence: strategies for study design and analysis. Oxford University Press, New York
37.
Zurück zum Zitat Goodwin PJ, Ennis M, Pritchard KI et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129PubMed Goodwin PJ, Ennis M, Pritchard KI et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129PubMed
39.
Zurück zum Zitat Nichols HB, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Holick CN, Egan KM (2007) Post-diagnosis weight change, body mass index, and breast cancer survival. In: Seventh annual AACR international conference on frontiers in cancer prevention. Washington, DC Nichols HB, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Holick CN, Egan KM (2007) Post-diagnosis weight change, body mass index, and breast cancer survival. In: Seventh annual AACR international conference on frontiers in cancer prevention. Washington, DC
40.
41.
Zurück zum Zitat Weaver TW, Kushi LH, McGovern PG et al (1996) Validation study of self-reported measures of fat distribution. Int J Obes Relat Metab Disord 20(7):644–650PubMed Weaver TW, Kushi LH, McGovern PG et al (1996) Validation study of self-reported measures of fat distribution. Int J Obes Relat Metab Disord 20(7):644–650PubMed
Metadaten
Titel
Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer
verfasst von
Bette J. Caan
Marilyn L. Kwan
Georgina Hartzell
Adrienne Castillo
Martha L. Slattery
Barbara Sternfeld
Erin Weltzien
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9203-0

Weitere Artikel der Ausgabe 10/2008

Cancer Causes & Control 10/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.